These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 12657912

  • 1. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997.
    Reis M, Lundmark J, Bengtsson F.
    Ther Drug Monit; 2003 Apr; 25(2):183-91. PubMed ID: 12657912
    [Abstract] [Full Text] [Related]

  • 2. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting.
    Reis M, Olsson G, Carlsson B, Lundmark J, Dahl ML, Wålinder J, Ahlner J, Bengtsson F.
    J Clin Psychopharmacol; 2002 Aug; 22(4):406-13. PubMed ID: 12172341
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic drug monitoring of escitalopram in an outpatient setting.
    Reis M, Chermá MD, Carlsson B, Bengtsson F, Task Force for TDM of Escitalopram in Sweden.
    Ther Drug Monit; 2007 Dec; 29(6):758-66. PubMed ID: 18043473
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic consequences of a citalopram treatment discontinuation.
    Voirol P, Rubin C, Bryois C, Kosel M, Buclin T, Baumann P.
    Ther Drug Monit; 1999 Jun; 21(3):263-6. PubMed ID: 10365634
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram.
    Le Bloc'h Y, Woggon B, Weissenrieder H, Brawand-Amey M, Spagnoli J, Eap CB, Baumann P.
    Ther Drug Monit; 2003 Oct; 25(5):600-8. PubMed ID: 14508384
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver.
    Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P.
    Biochem Pharmacol; 1998 Jul 01; 56(1):15-23. PubMed ID: 9698084
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Influence of concomitant medications on the total clearance and the risk for supra-therapeutic plasma concentrations of Citalopram. A population-based cohort study.
    Wenzel-Seifert K, Brandl R, Hiemke C, Haen E.
    Pharmacopsychiatry; 2014 Nov 01; 47(7):239-44. PubMed ID: 25372890
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.